A Phase 1 interventional study of SPD503 and VYVANSE in Healthy, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Drug-drug interaction study; to examine the pharmacokinetics of SPD503 and VYVANSE (lisdexamfetamine dimesylate) when given alone, and in combination.
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
First submitted before Shire became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Drug: SPD503
Drug: VYVANSE
Drug: SPD503 and VYVANSE
SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Also known as: guanfacine hydrochloride
VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Also known as: lisdexamfatamine dimesylate (LDX)
Drug pages: Guanfacine · Lisdexamfetamine
SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Maximum Plasma Concentration (Cmax) of Guanfacine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Time of Maximum Plasma Concentration (Tmax) of Guanfacine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Time of Plasma Half-Life(T 1/2) of Guanfacine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Cmax of d-Amphetamine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
AUC of d-Amphetamine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Tmax of d-Amphetamine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
T 1/2 of d-Amphetamine
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
| Milestone | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 6 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 | 7 | 6 |
| Completed | 7 | 7 | 6 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 | 7 | 6 |
| Completed | 7 | 7 | 6 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 | 7 | 6 |
| Completed | 7 | 7 | 6 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 6 | 7 | 7 | 6 |
| Completed | 7 | 7 | 6 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| ng/ml | SPD503 Alone | SPD503 + Vyvanse |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Guanfacine | 2.55 ± 1.03 | 2.97 ± 0.98 |
| ng*h/ml | SPD503 Alone | SPD503 + Vyvanse |
|---|---|---|
| Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine | 104.9 ± 34.7 | 112.8 ± 35.7 |
| hours | SPD503 Alone | SPD503 + Vyvanse |
|---|---|---|
| Time of Maximum Plasma Concentration (Tmax) of Guanfacine | 8.6 ± 7.7 | 7.9 ± 5.0 |
| hours | SPD503 Alone | SPD503 + Vyvanse |
|---|---|---|
| Time of Plasma Half-Life(T 1/2) of Guanfacine | 23.5 ± 10.2 | 21.4 ± 8.2 |
| ng/ml | Vyvanse Alone | SPD503 + Vyvanse |
|---|---|---|
| Cmax of d-Amphetamine | 36.48 ± 7.13 | 36.50 ± 6.00 |
| ng*h/ml | Vyvanse Alone | SPD503 + Vyvanse |
|---|---|---|
| AUC of d-Amphetamine | 686.9 ± 159.8 | 708.4 ± 137.8 |
| hours | Vyvanse Alone | SPD503 + Vyvanse |
|---|---|---|
| Tmax of d-Amphetamine | 4.2 ± 1.1 | 3.9 ± 1.1 |
| hours | Vyvanse Alone | SPD503 + Vyvanse |
|---|---|---|
| T 1/2 of d-Amphetamine | 11.2 ± 1.6 | 11.2 ± 1.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD503 Alone | — | 0/40 (0%) | 9/40 (22.5%) |
| Vyvanse Alone | — | 0/41 (0%) | 6/41 (14.6%) |
| SPD503 + Vyvanse | — | 0/41 (0%) | 6/41 (14.6%) |
| Event | SPD503 Alone | Vyvanse Alone | SPD503 + Vyvanse |
|---|---|---|---|
| Dizziness PosturalNervous system disorders | 4/40 | 1/41 | 0/41 |
| HeadacheNervous system disorders | 3/40 | 2/41 | 3/41 |
| DizzinessNervous system disorders | 2/40 | 3/41 | 3/41 |
| Age, Categorical(Participants) | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 7 | 7 | 7 | 7 | 7 | 42 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 30.9 ± 6.20 | 28.7 ± 8.44 | 34.6 ± 10.18 | 26.0 ± 5.29 | 31.9 ± 8.19 | 31.1 ± 4.18 | 30.5 ± 7.41 |
| Sex: Female, Male(Participants) | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 2 | 2 | 2 | 1 | 9 |
| Male | 6 | 6 | 5 | 5 | 5 | 6 | 33 |
| Region of Enrollment(Participants) | SPD503 First, Then Vyvanse, Then SPD503 + Vyvanse | SPD503 First, Then SPD503 + Vyvanse, Then Vyvanse | Vyvanse First, Then SPD503, Then SPD503 + Vyvanse | Vyvanse First, Then SPD503 + Vyvanse, Then SPD503 | SPD503 + Vyvanse First, Then SPD503, Then Vyvanse | SPD503 + Vyvanse, Then Vyvanse, Then SPD503 | Total |
|---|---|---|---|---|---|---|---|
| United States | 7 | 7 | 7 | 7 | 7 | 7 | 42 |
Ran from Jun 2009 to primary completion in Jul 2009, 1 month.
Results were first posted in Aug 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Guanfacine · Lisdexamfetamine